Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:46:08 17/07/2024 pm IST			5-day change	1st Jan Change
928.8 ^DKK	-4.24%		-4.86%	+33.05%

01:48pm	Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation	MT
10:56am	European shares slide as tech stocks weigh	RE

NOVO NORDISK : Sell rating from Jefferies

January 31, 2024 at 02:10 pm IST

Jefferies analyst Peter Welford reiterate his Sell rating on the stock. The target price is still set at DKK 465.

Latest news about Novo Nordisk A/S

Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation	05:18pm	MT
European shares slide as tech stocks weigh	02:26pm	RE
Dutch government should not subsidise weight-loss drug Wegovy, adviser says	02:20pm	RE
Roche reports positive early results in obesity drug trial	11:43am	RE
Dutch Health Care Wary of Reimbursing Novo Nordisk's Obesity Drug Cost	10:01am	MT
Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron	16/07	DJ
Novo owner backs Swiss biotech Asceneuron in $100 million round	16/07	RE
Health Care Declines on Regulatory Fears - Health Care Roundup	16/07	DJ
European Equities Close Lower in Monday Trading; Luxury Goods Stocks Fall as Burberry Reports 'Disappointing' Q1 Results, Fires CEO	15/07	MT
Novo Nordisk Says No Meeting Scheduled With US Senate Aides, Senior Executives	15/07	MT
Novo Nordisk Reported to Meet Senate Staff Over Decision to Discontinue Levemir Insulin	15/07	MT
Novo Nordisk Denies Reported Meeting with US Senate Aides Over Insulin Discontinuation	15/07	MT
Novo Nordisk to Meet US Senate Aides Over Levemir Insulin Sales Halt	15/07	MT
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	12/07	RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs	12/07	MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	12/07	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	12/07	RE
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says	12/07	MT
NOVO NORDISK : Buy rating from Deutsche Bank	12/07	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	12/07	DJ
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	11/07	MT
Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan...	11/07
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	11/07	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	11/07	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 10:06 pm IST

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 09:39 pm IST

Novo Nordisk doesn't disappoint

January 31, 2024 at 09:18 pm IST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

970 DKK

Average target price

956.8 DKK

Spread / Average Target

-1.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+33.05%	63TCr
ELI LILLY AND COMPANY	+61.53%	85TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ASTRAZENECA PLC	+13.58%	24TCr
NOVARTIS AG	+16.20%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	17TCr
SANOFI	+1.48%	13TCr

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Sell rating from Jefferies

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals